Assessing Lead Bioavailability in Environmental Me   3

Background
The U.S. Environmental Protection Agency (EPA) intends to negotiate a sole source contract with Burleson Research Technologies Inc. (BRTI) under the authority of 6.302-1. The contract is for conducting in vivo mouse assays for high priority research, including EPA’s Strategy to Reduce Lead Exposures and Disparities in U.S. Communities, and to address contaminated site cleanup and mitigation.

Work Details
BRTI will conduct mouse-based assays to determine the bioavailability of lead and arsenic in soil and dust samples selected by the EPA. The contractor will be provided with test diets amended with test materials from selected sites, and will perform assays of the provided test materials. At the end of the period of exposure, BRTI shall collect biological tissue samples and provide the EPA with all specified data collected during the performance of the assay, including daily food and water consumption data with specified biological samples collected.

Period of Performance
The acquisition will result in an Indefinite Delivery, Indefinite Quantity (ID/IQ) type contract, issuing Firm Fixed Price Task Orders. The contract is anticipated to be established in early December 2022.

Place of Performance
The work will be performed within a 10-15 minute commute range from EPA’s facility located in Research Triangle Park (RTP) North Carolina campus.